natgillin/translations-raw huggingface dataset:
I et studie med forebyggelse af tilbagefald, hvor patienterne blev randomiserede til enten duloxetin 60 mg eller placebo, efter 12-ugers akut behandling med open-label duloxetin 60 mg én gang dagligt viste duloxetin 60 mg én gang dagligt sig statistisk signifikant bedre end placebo (p=0,004) på den primære parameter, som var forebyggelsen af depressive tilbagefald målt som tid til tilbagefald. 
In a relapse prevention study, patients responding to 12-weeks of acute treatment with open-label duloxetine 60 mg once daily were randomised to either duloxetine 60 mg once daily or placebo for a further 6-months.
INDRE BLISTERKARTON TIL MULTIPAKNING MED 30 mg HÅRDE ENTEROKAPSLER, UDEN BLÅ BOKS 
BLISTER INNER CARTON FOR MULTIPACK FOR 30 MG HARD GASTRO RESISTANT CAPSULES, WITHOUT BLUE BOX
Duloxetine Mylan 30 mg hårde enterokapsler Duloxetine Mylan 60 mg hårde enterokapsler 
Duloxetine Mylan 30 mg hard gastro-resistant capsules Duloxetine Mylan 60 mg hard gastro-resistant capsules
PVC/PCTFE/Aluminium eller OPA/Aluminium/PVC - Aluminium-blisterpakning med 14, 28, 84, 98 og multipakninger med 98 (2 pakninger med 49) hårde enterokapsler. 
PVC/PCTFE/Aluminium or OPA/Aluminium/PVC - Aluminium blister pack containing 14, 28, 84, 98 and multipacks containing 98 (2 packs of 49) hard gastro resistant capsules.
Muskelstivhe d 
Muscle spasm
Perforeret enkeltdosisblisterpakning af PVC/PCTFE/Aluminium eller OPA/Aluminium/PVCAluminium med 28 x 1, 30 x 1 og 100 x 1 hårde enterokapsler. 
PVC/PCTFE/Aluminium or OPA/Aluminium/PVC - Aluminium perforated unit dose blister pack containing 28 x 1, 30 x 1 and 100 x 1 hard gastro resistant capsules PVC/PE/PVdC/Aluminium perforated unit dose blister pack containing 28 x 1 hard gastro-resistant capsules.
BLISTERKARTON TIL 60 mg HÅRDE ENTEROKAPSLER 
BLISTER CARTON FOR 60 MG HARD GASTRO RESISTANT CAPSULES
YDRE BLISTERKARTON TIL MULTIPAKNING MED 60 mg HÅRDE ENTEROKAPSLER, MED BLÅ BOKS 
BLISTER OUTER CARTON FOR MULTIPACK FOR 60 MG HARD GASTRO RESISTANT CAPSULES, WITH BLUE BOX
Hver kapsel indeholder 30 mg eller 60 mg duloxetin som hydrochlorid. 
Each capsule contains 30 mg or 60 mg of duloxetine (as hydrochloride).
• tidligere har haft tanker om at begå selvmord eller at gøre skade på dig selv. 
You may be more likely to think like this if you: - have previously had thoughts about killing or harming yourself - are a young adult.
PVC/PCTFE/Aluminium eller OPA/Aluminium/PVC - Aluminium-blisterpakning med 7, 14, 28, 98 og multipakninger med 98 (2 pakninger med 49) hårde enterokapsler. 
PVC/PCTFE/Aluminium or OPA/Aluminium/PVC - Aluminium blister pack containing 7, 14, 28, 98 and multipacks containing 98 (2 packs of 49) hard gastro-resistant capsules.
YDRE BLISTERKARTON TIL MULTIPAKNING MED 30 mg HÅRDE ENTEROKAPSLER, MED BLÅ BOKS 
BLISTER OUTER CARTON FOR MULTIPACK FOR 30 MG HARD GASTRO RESISTANT CAPSULES, WITH BLUE BOX
Duloxetine Mylan 60 mg hårde enterokapsler duloxetin 
Duloxetine Mylan 60 mg hard gastro-resistant capsules duloxetine
Muskelsitren 
Haemorrhage
Duloxetine Mylan 30 mg hårde enterokapsler duloxetin 
Duloxetine Mylan 30 mg hard gastro-resistant capsules duloxetine
PVC/PE/PVdC/Aluminium-blisterpakning med 7, 14, 28, 49, 98 og multipakninger med 98 (2 pakninger med 49) hårde enterokapsler. 
PVC/PE/PVdC/Aluminium blister pack containing 7, 14, 28, 49, 98 and multipacks containing 98 (2 packs of 49) hard gastro resistant capsules.
Du må kun stoppe behandlingen eller ændre dosis efter aftale med lægen. 
Do not stop taking Duloxetine Mylan, or change your dose, without talking to your doctor.
PVC/PE/PVdC/Aluminium-blisterpakning med 14, 28, 49, 98 og multipakninger med 98 (2 pakninger med 49) hårde enterokapsler. 
PVC/PE/PVdC/Aluminium blister pack containing 14, 28, 49, 98 and multipacks containing 98 (2 packs of 49) hard gastro-resistant capsules.
Apati 
Appetite
ETIKET TIL BEHOLDER TIL 30 mg HÅRDE ENTEROKAPSLER 
BOTTLE LABEL FOR 30 MG HARD GASTRO RESISTANT CAPSULES
Infektioner og parasitære sygdomme Laryngitis 
Renal and urinary disorders Dysuria
• samtidig tager anden medicin, som indeholder duloxetin (se ”Brug af anden medicin sammen med Duloxetine Mylan”). 
- are taking or have taken within the last 14 days, another medicine known as a monoamine oxidase inhibitor (MAOI) (see ‘Other medicines and Duloxetine Mylan') - are taking fluvoxamine which is usually used to treat depression, ciprofloxacin or enoxacin which are used to treat some infections - are taking other medicines containing duloxetine (see ‘Other medicines and Duloxetine Mylan')
Nattesved Urticaria Kontaktdermatitis Koldsved Lysfølsmheds -reaktioner Øget tendens til at få blå mærker 
Dermatitis contact Cold sweat Photo-sensitivity reactions
Stomatitis Hæmatokeksi 
Hepatic impairment
Nyrer og urinveje Dysuri 
Night sweats Urticaria
Blødning 
Somnolence
KARTON TIL BEHOLDER TIL 30 mg HÅRDE ENTEROKAPSLER 
BOTTLE CARTON FOR 30 MG HARD GASTRO RESISTANT CAPSULES
Duloxetin blev givet i to forskellige dagsdoser: 60 mg én gang dagligt og 60 mg to gange dagligt. 
In both studies, duloxetine 60 mg once daily and 60 mg twice daily significantly reduced pain compared with placebo.
KARTON TIL BEHOLDER TIL 60 mg HÅRDE ENTEROKAPSLER 
BOTTLE CARTON FOR 60 MG HARD GASTRO RESISTANT CAPSULES
I et studie med ældre depressive patienter ( 65 år), som viste en statistisk signifikant forskel i reduktionen i HAMD17-scoren for duloxetinbehandlede patienter sammenlignet med placebo, blev effekten af duloxetin 60 mg en gang dagligt særligt undersøgt. 
The effect of duloxetine 60 mg once a day in elderly depressed patients (≥65 years) was specifically examined in a study that showed a statistically significant difference in the reduction of the HAMD17
60 mg kapsler EU/1/15/1010/011 EU/1/15/1010/012 EU/1/15/1010/013 EU/1/15/1010/014 EU/1/15/1010/015 EU/1/15/1010/016 EU/1/15/1010/017 EU/1/15/1010/018 EU/1/15/1010/019 EU/1/15/1010/020 EU/1/15/1010/029 EU/1/15/1010/030 EU/1/15/1010/031 EU/1/15/1010/032 EU/1/15/1010/033 EU/1/15/1010/034 EU/1/15/1010/035 EU/1/15/1010/036 EU/1/15/1010/039 EU/1/15/1010/040 EU/1/15/1010/049 EU/1/15/1010/050 EU/1/15/1010/051 EU/1/15/1010/052 EU/1/15/1010/053 EU/1/15/1010/054 
EU/1/15/1010/016 EU/1/15/1010/017 EU/1/15/1010/018 EU/1/15/1010/019 EU/1/15/1010/020 EU/1/15/1010/029 EU/1/15/1010/030 EU/1/15/1010/031 EU/1/15/1010/032 EU/1/15/1010/033 EU/1/15/1010/034 EU/1/15/1010/035 EU/1/15/1010/036 EU/1/15/1010/039 EU/1/15/1010/040 EU/1/15/1010/049 EU/1/15/1010/050 EU/1/15/1010/051 EU/1/15/1010/052 EU/1/15/1010/053 EU/1/15/1010/054
EU/1/15/1010/004 EU/1/15/1010/005 EU/1/15/1010/006 EU/1/15/1010/007 EU/1/15/1010/008 EU/1/15/1010/009 EU/1/15/1010/010 EU/1/15/1010/021 EU/1/15/1010/022 EU/1/15/1010/023 EU/1/15/1010/024 EU/1/15/1010/025 EU/1/15/1010/026 EU/1/15/1010/027 EU/1/15/1010/028 EU/1/15/1010/037 EU/1/15/1010/038 EU/1/15/1010/041 EU/1/15/1010/042 EU/1/15/1010/043 EU/1/15/1010/044 EU/1/15/1010/045 EU/1/15/1010/046 EU/1/15/1010/047 EU/1/15/1010/048 
30 mg capsules EU/1/15/1010/001 EU/1/15/1010/002 EU/1/15/1010/003 EU/1/15/1010/004 EU/1/15/1010/005 EU/1/15/1010/006 EU/1/15/1010/007 EU/1/15/1010/008 EU/1/15/1010/009 EU/1/15/1010/010 EU/1/15/1010/021 EU/1/15/1010/022 EU/1/15/1010/023 EU/1/15/1010/024 EU/1/15/1010/025 EU/1/15/1010/026 EU/1/15/1010/027 EU/1/15/1010/028 EU/1/15/1010/037 EU/1/15/1010/038 EU/1/15/1010/041 EU/1/15/1010/042 EU/1/15/1010/043 EU/1/15/1010/044 EU/1/15/1010/045 EU/1/15/1010/046 EU/1/15/1010/047 EU/1/15/1010/048
Den anbefalede dosis af Duloxetine Mylan er 60 mg én gang dagligt. 
The usual dose of Duloxetine Mylan is 60 mg once a day, but your doctor will prescribe the dose that is right for you.
Hos de patienter, som responderede på 8-ugers akut behandling med 60 mg duloxetin en gang dagligt i et open-label, langtids, ukontrolleret studie, holdt smertereduktionen i yderligere 6 måneder. 
In an open label long-term uncontrolled study, the pain reduction in patients responding to 8-weeks of acute treatment of duloxetine 60 mg once daily was maintained for a further 6-months as measured by change on the Brief Pain Inventory (BPI) 24-hour average pain item.
(monoaminoxidasehæmmer) (se ”Brug af anden medicin sammen med Duloxetine Mylan”). 
(see ‘Pregnancy and breast-feeding) - are at risk of low sodium levels (for example if you are taking diuretics, especially if you are elderly) - are currently being treated with another medicine which may cause liver damage - are taking other medicines containing duloxetine (see ‘Other medicines and Duloxetine Mylan')
Dosering 
Laryngitis
Sløret syn Mydriasis Nedsat syn 
Mydriasis Visual impairment
Epistaxis 
Palpitations
Duloxetine Mylan er en hård enterokapsel. 
What Duloxetine Mylan looks like and contents of the pack Duloxetine Mylan is hard gastro-resistant capsule.
Generel unormal følelse 
Generalised anxiety disorder
Synkope Hypertension 
Hepatic failure Jaundice
MINDSTEKRAV TIL MÆRKNING PÅ BLISTER ELLER STRIP BLISTER TIL 30 mg HÅRDE ENTEROKAPSLER 
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
Perikon 
Excipients
Liste over lægemidlets navne, lægemiddelformer, styrker, indgivelsesvej samt indehavere af markedsføringstilladelse i medlemsstaterne 
List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, applicants and marketing authorisation holders in the member states
Consulting Ericapark 38 
Ericapark 38
Mercury Pharmaceuticals Limited 
Pharmaceuticals Limited
Addiscombe Road, Croydon, Surrey CR0 
Addiscombe Road, Croydon, Surrey CR0 0XT, United Kingdom
Koncentrat till infusionsvæske, opløsning 
Concentrate for solution for infusion
Magenta Pharma 
Belgium Magenta Pharma Consulting
1 mg/ml (5ml) Injektionsvæske, opløsning 
1 mg/ml (5ml)
Resultat af en procedure i henhold til artikel 30 i direktiv 2001/83/EF 
Outcome of a procedure under Article 30 of Directive 2001/83/EC
Der kan gives yderligere behandling under lægeligt opsyn. 
Further treatment can be given under medical supervision.
De harmoniserede afsnit omfatter: 
The areas harmonised include:
Europa-Kommissionen traf en afgørelse den 30 september 2010. 
The European Commission issued a decision on 30 September 2010.
Den virksomhed, der markedsfører disse lægemidler, er Leo Pharmaceutical Products. 
The company that markets these medicines is Leo Pharmaceutical Products.
Hvad er Daivobet? 
What is Daivobet?
Den anbefalede behandlingsperiode for salven er fire uger. 
The recommended treatment period for the ointment is four weeks.
Jens Ersbøll (Danmark) 
Jens Ersbøll (Denmark)
Daivobet salve blev i nogle medlemsstater godkendt via en gensidig anerkendelsesprocedure og i andre medlemsstater via nationale procedurer. 
Daivobet ointment was authorised in some Member States through a mutual recognition procedure and in others through national procedures.
Der bør ikke anvendes mere end 15 g gel eller salve om dagen. 
No more than 15 g of the gel or ointment should be used in one day.
Daivobet gel blev godkendt via en decentral procedure. 
Daivobet gel was authorised via a decentralised procedure.
Hvorfor blev Daivobet undersøgt igen? 
Why was Daivobet reviewed?
Daivobet indeholder to aktive stoffer: calcipotriol og betamethason. 
Daivobet contains two active substances: calcipotriol and betamethasone.
Det fås som gel og salve, og det anvendes topisk (smøres på huden). 
It is available as a gel and ointment and is used topically (applied on the skin).
Det Europæiske Lægemiddelagentur (EMA) har foretaget en revurdering af Daivobet. 
The European Medicines Agency has completed a review of Daivobet.
Daivobet fås også i EU under handelsnavnet Dovobet. 
Daivobet is also available in the EU under the trade name Dovobet.
Den 10. marts 2010 indbragte Leo Pharmaceutical Products Daivobet for CHMP med henblik på at harmonisere markedsføringstilladelserne for lægemidlet i EU. 
On 10 March 2010, Leo Pharmaceutical Products referred Daivobet to the CHMP in order to harmonise the marketing authorisations for the product in the EU.
Derfor er der nogle forskelle i produktresuméerne, etiketteringen og indlægssedlerne i de lande, hvor lægemidlerne bliver markedsført. 
Because of this, there are some differences in the summaries of product characteristics (SmPCs), labelling and package leaflets in the countries where the medicines are marketed.
Udvalget harmoniserede ligeledes en liste over kontraindikationer i forbindelse med hudsygdomme, herunder virale hudlæsioner, svampe- eller bakterieinfektioner, parasitinfektioner og hudproblemer som følge af tuberkulose eller syfilis. 
The Committee also harmonised a list of contra-indications related to skin conditions, including viral lesions of the skin, fungal or bacterial skin infections, parasitic infections and skin problems caused by tuberculosis or syphilis.
Spørgsmål og svar vedrørende Daivobet og tilknyttede navne (calcipotriol/betamethason gel og salve, 50 mikrogram/0,5 mg/g) EMA/CHMP/466386/2010 
Questions and answers on Daivobet and associated names (calcipotriol/betamethasone gel and ointment, 50 micrograms/0.5 mg per g) EMA/CHMP/466386/2010
EMA's Udvalg for Lægemidler til Mennesker (CHMP) konkluderede, at der er behov for at harmonisere ordinationsoplysningerne for Daivobet i Den Europæiske Union (EU). 
The Agency's Committee for Medicinal Products for Human Use (CHMP) has concluded that there is a need to harmonise the prescribing information for Daivobet in the European Union (EU).
Spørgsmål og svar vedrørende Daivobet og tilknyttede navne (calcipotriol/betamethason gel og salve, 50 mikrogram/0,5 mg/g) 
Questions and answers on Daivobet and associated names (calcipotriol/betamethasone gel and ointment, 50 micrograms/0.5 mg per g)
Daivobet må heller ikke anvendes hos patienter med unormale calciumniveauer i blodet. 
It must also not be used in patients with abnormal levels of calcium in their blood.
Den fuldstændige liste fremgår af det harmoniserede produktresumé. 
For the full list, see the harmonised SmPC.
På grundlag af de fremlagte oplysninger og den faglige drøftelse i udvalget var CHMP af den opfattelse, at produktresuméet, etiketteringen og indlægssedlen skulle harmoniseres inden for EU. 
The CHMP, in the light of the data submitted and the scientific discussion within the Committee, was of the opinion that the SmPCs, labelling and package leaflets should be harmonised across the EU.
Udvalget harmoniserede ligeledes andre punkter i produktresuméet, herunder punkterne om særlige advarsler, fertilitet, graviditet og amning samt bivirkninger. 
The Committee also harmonised other sections of the SmPC, including the sections on special warnings, pregnancy and lactation and undesirable effects.
22. juli 2010 
22 July 2010
Daivobet må ikke anvendes hos patienter, der har visse typer psoriasis, som er rødt og skællende eller fydt med pus. 
Daivobet must not be used in patients who have some types of psoriasis that is red and flaking off or filled with pus.
CHMP vedtog, at Daivobet salve skulle bruges til behandling af voksne med plaque-psoriasis, når det er muligt at bruge et topisk lægemiddel. 
The CHMP agreed that Daivobet ointment is to be used for the treatment of adults with plaque psoriasis where it is possible to use a topical medicine.
Daivobet bør ikke anvendes hos patienter, der kan være overfølsomme (allergiske) over for det aktive stof eller over for et eller flere af hjælpestofferne. 
Daivobet should not be used in patients who may be hypersensitive (allergic) to the active substances or to any other ingredient.
Daivobet anvendes til behandling af voksne med psoriasis (en sygdom, der medfører røde, skællende pletter på huden). 
Daivobet is used to treat adults with psoriasis (a disease causing red, scaly patches on the skin).
For gelen er den anbefalede behandlingsperiode fire uger for psoriasis i hovedbunden og otte uger for psoriasis andre steder end i hovedbunden. 
For the gel, the recommended treatment period is four weeks for scalp psoriasis and eight weeks for non-scalp psoriasis.
Calcipotriol er et stof, der stammer fra D-vitamin, og som virker via receptorer i huden og hindrer den celledeling, der er årsag til de skællende pletter ved psoriasis. 
Calcipotriol, a substance derived from vitamin D, acts through receptors in the skin to prevent the multiplication of cells that cause the scaly patches in psoriasis.
Betamethason er et betændelseshæmmende lægemiddel, som er med til at mindske den betændelse og kløe, der optræder i forbindelse med psoriasis. 
Betamethasone is an anti-inflammatory medicine that helps to reduce the inflammation and itching that occur with psoriasis.
Daivobet skal smøres på de berørte hudområder én gang om dagen. 
Daivobet should be applied once a day on the affected areas of the skin.
Daivobet gel anvendes til behandling af psoriasis i hovedbunden eller mild til moderat plaque-psoriasis andre steder på kroppen. 
Daivobet gel is for the treatment of psoriasis on the scalp or mild to moderate plaque psoriasis on other parts of the body.
4.2 Dosering og indgivelsesvej 
4.2 Posology and method of administration
Dato for virksomhedens svar: 
Company responses provided on: 16 June 2010 Opinion date:
Drik den med det samme. 
Drink it straight away.
, øget appetit. 
, increased appetite.
Der er ingen tilstrækkelige og velkontrollerede undersøgelser af gravide kvinder. 
There are no adequate and well-controlled studies in pregnant women.
Placér tabletten i din mund. 
Place the tablet in your mouth.
Der udvikledes tolerance overfor CNS depressionen. 
Tolerance developed to the CNS depression.
Med nogle drikkevarer kan blandingen ændre farve og måske blive uklar. 
With some drinks, the mixture may change colour and possibly become cloudy.
Forøget total bilirubin 
Increased total bilirubin
I en undersøgelse af kaukasiske, japanske og kinesiske individer fandtes ingen forskel i farmakokinetiske parametre i de tre populationsgrupper. 
In a study of Caucasians, Japanese, and Chinese subjects, there were no differences in the pharmacokinetic parameters among the three populations.
Restless legs-syndrom 
Restless legs syndrome
Glukosuri Øget appetit 
Glucosuria Increased appetite
Der er ikke foretaget undersøgelser af virkninger på evnen til at føre motorkøretøj og betjene maskiner. 
No studies on the effects on the ability to drive and use machines have been performed.
Alternativt kan den dispergeres i et helt glas vand eller anden egnet væske (appelsinjuice, æblejuice, mælk eller kaffe) umiddelbart før administration. 
Alternatively, it may be dispersed in a full glass of water or other suitable beverage (orange juice, apple juice, milk or coffee) immediately before administration.
Håndter ikke tabletterne med våde hænder, da tabletterne kn knække. 
Do not handle the tablets with wet hands as the tablets may break up.
Når mere end én parameter, som kan føre til nedsat metabolisering, er til stede (kvinder, ældre, ikke-rygere), bør det overvejes at reducere startdosis. 
When more than one factor is present which might result in slower metabolism (female gender, geriatric age, non-smoking status), consideration should be given to decreasing the starting dose.
Dyskinesi6 
Dyskinesia6
Unge (alder 13-17 år): Farmakokinetikken af olanzapin er den samme hos unge og voksne. 
Adolescents (ages 13 to 17 years): The pharmacokinetics of olanzapine are similar between adolescents and adults.
• Medicin for Parkinsons sygdom. 
• medicines for Parkinson's disease.
Optrapning af dosis, når indiceret, bør hos sådanne patienter foretages med forsigtighed. 
Dose escalation, when indicated, should be conservative in such patients.
Aktivt kul reducerer biotilgængeligheden af oral olanzapin med 50 til 60 % og bør tages mindst 2 timer før eller efter olanzapin. 
Activated charcoal reduces the bioavailability of oral olanzapine by 50 to 60% and should be taken at least 2 hours before or after olanzapine.
I tilfælde af moderat leverinsufficiens (cirrhosis, Child-Pugh klasse A eller B) bør startdosis være 5 mg og bør kun øges med forsigtighed. 
In cases of moderate hepatic insufficiency (cirrhosis, Child-Pugh Class A or B), the starting dose should be 5 mg and only increased with caution.
Du eller dine pårørende kan også indberette bivirkninger direkte til Sundhedsstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel. 
You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.
Meget almindelig: Sedation (inklusive: hypersomni, letargi, somnolens). 
Very common: Sedation (including: hypersomnia, lethargy, somnolence).
På baggrund af resultater fra undersøgelser af mus og rotter blev det konkluderet, at olanzapin ikke er karcinogent. 
Based on the results of studies in mice and rats, it was concluded that olanzapine is not carcinogenic.
Klinisk signifikant vægtøgning (≥ 7 %) synes at forekomme hyppigst i den unge population sammenlignet med ældre med sammenlignelig eksponering. 
Clinically significant weight gain (≥ 7%) appears to occur more frequently in the adolescent population compared to adults with comparable exposures.
I undersøgelser af op til 3 måneders varighed af mus og op til 1 års varighed af rotter og hunde var CNS depression, antikolinerge effekter og perifere hæmatologiske forstyrrelser de dominerende effekter. 
In studies up to 3 months duration in mice and up to 1 year in rats and dogs, the predominant effects were CNS depression, anticholinergic effects, and peripheral haematological disorders.
• Periodiske, opdaterede sikkerhedsindberetninger (PSUR'er) 
• Periodic Safety update Reports
Meget sjældne bivirkninger omfatter alvorlige allergiske reaktioner, såsom lægemiddelreaktion med eosinofili og systemiske symptomer (DRESS). 
Very rare side effects include serious allergic reactions such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).
• Fortæl det til lægen, hvis du eller nogen i din familie tidligere har haft blodpropper, da denne type medicin kan være forbundet med dannelse af blodpropper 
• Tell the doctor if you or someone else in your family has a history of blood clots, as medicines like these have been associated with formation of blood clots.
Dystoni (inklusive okulogyration)11 
Dystonia (including oculogyration) 11
16 Forhøjede plasmaprolaktinniveauer blev rapporteret hos 47,4 % af de unge patienter. 
Elevated plasma prolactin levels were reported in 47.4% of adolescent patients.
Graviditet og amning Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal du spørge din læge til råds, før du tager dette lægemiddel. 
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
98 tabletter. 
and 98 tablets.
Voksne Olanzapin er indiceret til behandling af skizofreni. 
Adults Olanzapine is indicated for the treatment of schizophrenia.
Du kan også placere tabletten i et helt glas vand, appelsinjuice, æblejuice, mælk eller kaffe og rør rundt. 
You can also place the tablet in a full glass or cup of water, orange juice, apple juice, milk or or coffee and stir.
• hvis du tidligere har fået at vide, at du har en bestemt slags glaukom (grøn stær) med øget tryk i øjet. 
• If you have been previously diagnosed with eye problems such as certain kinds of glaucoma (increased pressure in the eye).
I 2 ud af 2 placebo- og 2 ud af 3 komparatorkontrollerede undersøgelser af mere end 2.900 skizofrene patienter med både positive og negative symptomer blev olanzapin forbundet med statistisk signifikante større forbedringer af negative såvel som af positive symptomer. 
In two of two placebo and two of three comparator controlled trials with over 2,900 schizophrenic patients presenting with both positive and negative symptoms, olanzapine was associated with statistically significantly greater improvements in negative as well as positive symptoms.
Olanzapin (5-20 mg) udviste imidlertid en sammenlignelig sikkerhedsprofil hos kvindelige (n=467) som hos mandlige patienter (n=869). 
However, olanzapine (5-20 mg) demonstrated a comparable safety profile in female (n = 467) as in male patients (n = 869).
Den anbefalede startdosis er 10 mg/dag. 
The recommended starting dose is 10 mg/day.